Glisen MF 1 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. This dual mechanism addresses both insulin deficiency and insulin resistance, making Glisen MF 1 Tablet PR effective in achieving optimal blood glucose levels in patients inadequately controlled by diet and exercise alone. The prolonged-release formulation ensures steady plasma drug concentrations, minimizing peak-related side effects and enhancing patient compliance. It is recommended to be administered with meals to reduce gastrointestinal discomfort commonly associated with Metformin. Caution is advised in patients with renal impairment, hepatic dysfunction, or a history of lactic acidosis. Regular monitoring of blood glucose levels, renal function, and potential adverse effects such as hypoglycemia is essential during therapy. Glisen MF 1 Tablet PR should be used as part of a comprehensive diabetes management plan, including lifestyle modifications, to achieve and maintain glycemic targets and reduce the risk of diabetes-related complications.